This report details Abbott Laboratories' recent financial performance, highlighting how a reduced annual earnings forecast overshadowed an otherwise strong quarterly earnings report. It explores the company's divisional growth, challenges, and strategic acquisitions, concluding with the market's negative reaction.
Despite Strong Performance, Revised Outlook Drags Down Investor Sentiment
Quarterly Earnings Exceed Projections, But Future Outlook Dims
The global healthcare giant announced its quarterly financial outcomes, revealing sales of $11.16 billion, which surpassed the analyst consensus of $10.99 billion. Furthermore, Abbott's adjusted earnings reached $1.15 per share, outperforming both Wall Street's expectation of $1.14 and its own internal guidance of $1.12-$1.18 per share. The company experienced a 7.8% increase in sales on a reported basis, and a 3.7% rise on a comparable basis, factoring in the integration of Exact Sciences.
Medical Device and Diabetes Care Sectors Propel Growth
The medical devices division demonstrated significant strength, with sales climbing 13.2% on a reported basis to $5.54 billion, and 8.5% on a comparable basis. This expansion was largely fueled by double-digit growth across its Electrophysiology, Heart Failure, and Rhythm Management segments. Similarly, the Diabetes Care sector reported sales of approximately $2.08 billion, with continuous glucose monitor sales increasing by 14.2% on a reported basis and 7.6% on a comparable basis.
Diagnostics Face Challenges Amidst Mild Respiratory Season
The diagnostics division presented a more varied performance. Sales grew 6.1% on a reported basis to $2.18 billion, and 1.8% on a comparable basis. Core Laboratory Diagnostics, generating $1.27 billion, saw growth primarily in the U.S., Europe, and Latin America, with an increase in both year-over-year and sequential sales. However, Rapid and Molecular Diagnostics experienced reduced demand for respiratory virus tests due to a less severe respiratory virus season compared to the previous year. Additionally, Nutrition sales declined by 6% (-7.7% on a comparable basis) to $2.02 billion, attributed to lower sales volumes and strategic pricing adjustments in late 2025. Conversely, Established Pharmaceuticals sales surged 13.2% (+9% on a comparable basis), reaching $1.43 billion.
Revised Annual Guidance Impacts Investor Confidence
On Thursday, Abbott Laboratories announced an adjusted earnings forecast for the second quarter of 2026, ranging from $1.25-$1.31, which fell below the consensus estimate of $1.37. The company further revised its fiscal year 2026 adjusted earnings guidance downward, from an initial $5.55-$5.80 per share to $5.38-$5.58 per share, missing the Wall Street consensus of $5.62. This updated guidance includes a 20-cent per share dilution resulting from the acquisition of Exact Sciences. Despite this, the company projects fiscal 2026 comparable sales growth between 6.5% and 7.5%. Chairman and CEO Robert Ford stated during an investor call that the Exact Sciences acquisition is expected to add approximately $3 billion in incremental sales in 2026, thereby accelerating Abbott's long-term sales growth rate.
Abbott's Stock Reaches New Low
Following these announcements, Abbott Laboratories shares experienced a significant drop, falling 4.76% to $96.72. This downturn pushed the stock to a new 52-week low, according to market data.
